Cargando…

OR23-06 Is the Improved Glucose Homeostasis in Patients with Acromegaly Treated with Pegvisomant Caused by Improved Glucagon Secretion?

Context: Active acromegaly is associated with impaired glucose metabolism, which improves upon treatment. Treatment with first generation somatostatin analogues (SSA) has a detrimental effect on insulin secretion, but the effect on glucose homeostasis is neutralized by the reduction in growth hormon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jørgensen, miss, Nanna Thurmann, Erichsen, Trine Møller, Klose, Marianne C, Jørgensen, Morten Buus, Idorn, Thomas, Rasmussen, Bo F, Holst, Jens J, Rasmussen, Ulla Feldt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207322/ http://dx.doi.org/10.1210/jendso/bvaa046.1827

Ejemplares similares

SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant
por: Wajnrajch, Michael, et al.
Publicado: (2019)

SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience
por: Wajnrajch, Michael, et al.
Publicado: (2019)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
por: Tatsi, Christina, et al.
Publicado: (2021)

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)
por: Samson, Susan, et al.
Publicado: (2019)

OR06-05 Inadequate High Mitochondrial ATP-Synthesis Explains “Non-Fatty-Liver” in Patients with Acromegaly
por: Fellinger, Paul, et al.
Publicado: (2020)

ODP350 Safety and Efficacy of Tesomet over 48 Weeks of Treatment: Results From a 24-Week Phase 2, Randomized, Double-Blind Study With 24 Week Open-Label Extension in Adults With Hypothalamic Obesity
por: Klose, Marianne, et al.
Publicado: (2022)

THU071 Key Device Attributes For Injectable SRL Therapy In Acromegaly And NETs To Aid Clinical Decision Making
por: de Herder, Wouter W, et al.
Publicado: (2023)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

SAT-439 Impact on Health Care Resources: A Comparison of Costs Following Treatment with Pegvisomant and Somatostatin Analogues Using Optum Claims Database
por: Kelepouris, Nicky, et al.
Publicado: (2019)

SAT-444 Pituitary Function and the Response to GH Replacement Therapy in Patients with Histiocytosis: Analysis of the Pfizer International Metabolic Database (KIMS)
por: Touraine, Philippe, et al.
Publicado: (2019)

THU120 Validation Of A Novel Automated System, Fluispotter®, For Serial Sampling Of Dried Blood Spots
por: Krogh, Jesper, et al.
Publicado: (2023)

ODP320 Immune Organs Enlarged in Acromegaly: Evaluation of Thymus Volume in Patients with Acromegaly
por: Nahit Sendur, Suleyman, et al.
Publicado: (2022)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

MON-452 Development of Concepts for Improved Patient Care: What Do Patients with Acromegaly Expect from Their Caregivers?
por: Kreitschmann-Andermahr, Ilonka, et al.
Publicado: (2019)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
por: Fleseriu, Maria, et al.
Publicado: (2021)

THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide
por: Samson, Susan Leanne, et al.
Publicado: (2023)

SAT-451 Acromegaly and Thyroid Cancer
por: Danilowicz, Karina, et al.
Publicado: (2019)

SAT-257 Coexisting Craniopharyngioma and Acromegaly
por: Yang, Almira, et al.
Publicado: (2020)

Pleurihormonal Pituitary Adenomas Presenting as Acromegaly
por: Schwehr, Megan, et al.
Publicado: (2021)

The Secret Behind Anemia in Patients With Acromegaly
por: Firlatan, Busra, et al.
Publicado: (2021)

THU025 Acromegaly And Central Hyperthyroidism
por: Akhtar, Ahmad, et al.
Publicado: (2023)

THU060 Time To First Remission, Medical Therapy And Survival In Acromegaly: UK Acromegaly Register (UKAR) Study
por: Deshmukh, Harshal, et al.
Publicado: (2023)

Use of Oral Concomitant Medications in Patients With Acromegaly
por: Petersenn, Stephan, et al.
Publicado: (2021)

ODP314 Gynecomastia as the Initial Presentation of Acromegaly.
por: Lim, Frederick, et al.
Publicado: (2022)

ODP306 Diplopia as Presenting Manifestation of Acromegaly
por: Rjoob, Hani, et al.
Publicado: (2022)

FRI356 SIADH In Acromegaly And Cerebrovascular Accident
por: Simrampreet, Gill, et al.
Publicado: (2023)

OR06-06 Pituitary Tumors and Immortalized Cell Lines Generated by Cre-Inducible Expression of SV40 T-Antigen
por: Mortensen, Amanda Helen, et al.
Publicado: (2020)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

MON-302 The Prevalence of Acromegaly in the Sleep Apnoea Clinic
por: Lynch, Julie Marie, et al.
Publicado: (2020)

SAT-267 Pregnancy in Acromegaly: Report of Five Cases
por: Burcea, Iulia Florentina, et al.
Publicado: (2020)

Pachydermoperiostosis: A Rare Masquerader of Acromegaly and Thyroid Acropachy
por: Alkaissi, Hussam R, et al.
Publicado: (2021)

THU022 A Case Of Delayed Diagnosis Of Acromegaly
por: Blanchard, Kayla, et al.
Publicado: (2023)

SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database
por: Amodru, Vincent, et al.
Publicado: (2020)

SAT-249 Polyarticular Osteoarthritis: A Disabling Manifestation of Acromegaly
por: Khan, Azkia, et al.
Publicado: (2020)

MON-LB52 Evaluation of Arterial Stiffness in Acromegaly Patients
por: alagüney, sevil, et al.
Publicado: (2020)

MON-310 Factors Associated with Remission After Surgery for Acromegaly
por: Cunha, Clara, et al.
Publicado: (2020)

SAT-251 New Diagnosis of Acromegaly with DKA as Initial Presentation
por: Gundluru, Rajani, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6uin12j5ig672rvlhgmglbt9vs